Deepa Lalla

2.3k total citations · 1 hit paper
55 papers, 1.8k citations indexed

About

Deepa Lalla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Deepa Lalla has authored 55 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Deepa Lalla's work include HER2/EGFR in Cancer Research (28 papers), Cancer Treatment and Pharmacology (24 papers) and Breast Cancer Treatment Studies (15 papers). Deepa Lalla is often cited by papers focused on HER2/EGFR in Cancer Research (28 papers), Cancer Treatment and Pharmacology (24 papers) and Breast Cancer Treatment Studies (15 papers). Deepa Lalla collaborates with scholars based in United States, Canada and France. Deepa Lalla's co-authors include Angelika Jahreis, David Cella, Michael Woolley, Ken Gordon, Ranga Krishnan, Kim Papp, Stephen K. Tyring, Craig L. Leonardi, Alice B. Gottlieb and Andrea Wang and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Deepa Lalla

52 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

2005 852 citations Stephen K. Tyring, Alice B. Gottlieb et al. The Lancet profile →

Peers

Deepa Lalla

IMMUN

ONCOL

DERMA

Akihiro Hirakawa Japan

Déborah Bauer United States

Diana Lüftner Germany

Fariborz Mobarrez Sweden

Bradford R. Hirsch United States

Raj Tummala United States

Alissa Kapke United States

Manuel Benavides Spain

Donald A. Barkauskas United States

Thomas Masterman Sweden

Akihiro Hirakawa Japan

Deepa Lalla

213 ×0.4

IMMUN

314 ×0.7

ONCOL

112 ×0.3

14 ×0.0

DERMA

66 ×0.2

Citations per year, relative to Deepa Lalla Deepa Lalla (= 1×) peers Akihiro Hirakawa

Countries citing papers authored by Deepa Lalla

Since Specialization

Citations

This map shows the geographic impact of Deepa Lalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepa Lalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepa Lalla more than expected).

Fields of papers citing papers by Deepa Lalla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepa Lalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepa Lalla. The network helps show where Deepa Lalla may publish in the future.

Co-authorship network of co-authors of Deepa Lalla

This figure shows the co-authorship network connecting the top 25 collaborators of Deepa Lalla. A scholar is included among the top collaborators of Deepa Lalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepa Lalla. Deepa Lalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hendrix, Nathaniel, Nina Oestreicher, Deepa Lalla, et al.. (2022). Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clinical Breast Cancer. 22(8). 781–791. 1 indexed citations

Mahtani, Reshma, et al.. (2021). Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents. Clinical Breast Cancer. 22(4). e488–e496. 5 indexed citations

Garrison, Louis P., Joseph B. Babigumira, Anthony Masaquel, et al.. (2015). The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health. 18(4). 541–546. 14 indexed citations

Danese, Mark D., et al.. (2015). Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Value in Health. 18(6). 876–883. 9 indexed citations

Kaufman, Peter A., Kenneth J. Bloom, Howard A. Burris, et al.. (2014). Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. 120(17). 2657–2664. 47 indexed citations

Guérin, Annie, Deepa Lalla, Geneviève Gauthier, et al.. (2014). Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. SpringerPlus. 3(1). 236–236. 4 indexed citations

Parthan, Anju, Laura Becker, Arthur M. Small, et al.. (2014). Health Care Utilization and Costs by Site of Service for Nonmetastatic Breast Cancer Patients Treated with Trastuzumab. Journal of Managed Care Pharmacy. 20(5). 485–493. 6 indexed citations

Hansen, Ryan N., Scott D. Ramsey, Deepa Lalla, et al.. (2014). Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. SpringerPlus. 3(1). 259–259. 24 indexed citations

Lalla, Deepa, et al.. (2014). Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. SpringerPlus. 3(1). 350–350. 17 indexed citations

10.

Welslau, Manfred, Véronique Dièras, Joohyuk Sohn, et al.. (2013). Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Cancer. 120(5). 642–651. 90 indexed citations

11.

Au, Heather‐Jane, W. Eiermann, Nicholas J. Robert, et al.. (2013). Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study. The Oncologist. 18(7). 812–818. 19 indexed citations

12.

Hurvitz, Sara A., Deepa Lalla, Ross D. Crosby, & Susan D. Mathias. (2013). Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Research and Treatment. 142(3). 603–609. 23 indexed citations

13.

Griffiths, Robert I., Deepa Lalla, Robert J. Herbert, et al.. (2011). Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Cancer Investigation. 29(9). 573–584. 16 indexed citations

14.

Rugo, Hope S., Melissa Brammer, Fan Zhang, & Deepa Lalla. (2010). Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials. Clinical Breast Cancer. 10(4). 288–293. 15 indexed citations

15.

Danese, Mark D., Deepa Lalla, Melissa Brammer, Quan V. Doan, & Kevin Knopf. (2010). Estimating recurrences prevented from using trastuzumab in HER‐2/neu–positive adjuvant breast cancer in the United States. Cancer. 116(24). 5575–5583. 10 indexed citations

16.

McMillan, Robert, James B. Bussel, James N. George, Deepa Lalla, & Janet L. Nichol. (2007). Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura. American Journal of Hematology. 83(2). 150–154. 118 indexed citations

17.

Garrison, L., et al.. (2006). Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. Journal of Clinical Oncology. 24(18_suppl). 6023–6023. 7 indexed citations

18.

Tyring, Stephen K., Alice B. Gottlieb, Kim Papp, et al.. (2005). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. The Lancet. 367(9504). 29–35. 852 indexed citations breakdown →

19.

Krueger, Gerald G., Richard G. Langley, A.Y. Finlay, et al.. (2005). Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. British Journal of Dermatology. 153(6). 1192–1199. 118 indexed citations

20.

Feldman, Steven R., Alexa B. Kimball, Gerald G. Krueger, et al.. (2005). Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. Journal of the American Academy of Dermatology. 53(5). 887–889. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact